Recombinant anti-GPIIb/IIIa antibodies

Abstract

The invention relates to novel nucleic acid sequences which encode human autoantibodies and antiidiotypic antibodies against blood platelet membrane proteins, to novel amino acid sequences of human antibodies, and to their use for the diagnosis and therapy of diseases.

1 . A polypeptide encoded by a nucleic acid which encodes a heavy chain, which is able to bind to GPIIb/IIIa, of a human antibody, or a functional derivative or a fragment thereof, and comprising a CDR3 region, selected from: 
 (a) a nucleotide sequence which encodes the amino acid sequence: VLPFDPISMDV,    (b) a nucleotide sequence which encodes the amino acid sequence ALGSWGGWDHYMDV, and    (c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).    
     
     
         2 . The polypeptide according to  claim 1 , wherein it comprises the variable domain of the H chain and/or the variable domain of the L chain of a human body.  
     
     
         3 . The polypeptide according to  claim 2 , wherein it comprises both the variable domain of the H chain and the variable domain of the L chain.  
     
     
         4 . The polypeptide according to  claim 1 , wherein said polypeptide is coupled to a labeling group or a toxin.  
     
     
         5 . A pharmaceutical composition which comprises, as the active component, a polypeptide according to  claim 1 , in combination with other active components, pharmaceutically customary adjuvants, additives and/or excipients.  
     
     
         6 . A method for preparing an agent for the diagnosis or for the treatment or prevention of AITP comprising: 
 providing a polypeptide according to  claim 1 , and combining with a pharmaceutically acceptable carrier, thereby preparing an agent for the diagnosis or for the treatment or prevention of AITP.    
     
     
         7 . A method for affecting the binding of fibrinogen to blood platelets, comprising administering a polypeptide according to  claim 1  in an amount sufficient to exert an effect on the binding of fibrinogen to blood platelets.  
     
     
         8 . A method for modulating blood coagulation, comprising administering a polypeptide according to  claim 1  in an amount suitable for dissolving thrombi and/or inhibiting the formation of thrombi.